Clinical Trial Update: Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating second-generation anti-CEA designer T cells in metastatic breast cancer, with the trial currently suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 2nd Generation Anti-CEA Designer T Cells

Snippet

Sponsor: Roger Williams Medical Center | Conditions: Breast Cancer | Phase 1 | Status: SUSPENDED